/BOLD
BOLD Stock - Boundless Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$1.22-3.94%
$0.05 (-3.94%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BOLD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.21 – $1.23
TARGET (TP)$1.40
STOP LOSS$1.12
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.04
52W High$3.12
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,086,000 | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-73,267,000 | $-54,796,000 | $-46,469,000 | $-25,301,000 | $-134,372,000 |
| Net Income | $-65,363,000 | $-49,434,000 | $-45,901,000 | $-25,210,000 | $-128,821,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.85 | $-2.22 | $-2.06 | $-1.13 | $-2.93 |
Company Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 1162.3% Upside
Now
$3
Low
$15
Average
$25
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | H.C. Wainwright | Initiation | Buy | $5 |
| May 28th 2025 | Leerink Partners | Downgrade | Market Perform | $3 |
| December 13th 2024 | Guggenheim | Downgrade | Neutral | - |
| April 22nd 2024 | Piper Sandler | Initiation | Overweight | $20 |
| April 22nd 2024 | Guggenheim | Initiation | Buy | $24 |
| April 22nd 2024 | Leerink Partners | Initiation | Outperform | $25 |
Earnings History & Surprises
BOLDBeat Rate
46%
Last 13 quarters
Avg Surprise
-167.0%
EPS vs Estimate
Beats / Misses
6/6
1 met exactly
Latest EPS
$-0.62
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
-2130.9%
$-12.27vs$-0.55
Q3 24
+1.3%
$-0.77vs$-0.78
Q4 24
+2.6%
$-0.74vs$-0.76
Q1 25
0.0%
$-0.74vs$-0.74
Q2 25
-4.4%
$-0.71vs$-0.68
Q3 25
+6.7%
$-0.70vs$-0.75
Q4 25
-17.0%
$-0.62vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.44 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.53 | $-0.62 | -17.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.68 | $-0.71 | -4.4% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.74 | $-0.74 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $-0.76 | $-0.74 | +2.6% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.78 | $-0.77 | +1.3% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.55 | $-12.27 | -2130.9% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-0.55 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.59 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.56 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-0.53 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.53 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.59 | — | — |
Q4 2019 | Nov 7, 2019 | $-1.07 | $-1.00 | +6.5% | ✓ BEAT |
Q3 2019 | Aug 6, 2019 | $-1.04 | $-1.01 | +2.9% | ✓ BEAT |
Q2 2019 | May 7, 2019 | $-0.89 | $-1.13 | -27.0% | ✗ MISS |
Q1 2019 | Feb 27, 2019 | $-0.91 | $-0.84 | +7.7% | ✓ BEAT |
Q4 2018 | Nov 6, 2018 | $-0.88 | $-0.97 | -10.2% | ✗ MISS |
Q3 2018 | Aug 7, 2018 | $-0.78 | $-0.85 | -9.0% | ✗ MISS |
Frequently Asked Questions about BOLD
What is BOLD's current stock price?
Boundless Bio, Inc. (BOLD) is currently trading at $1.22 per share. The stock has moved -3.94% today.
What is the analyst price target for BOLD?
No analyst price targets are currently available for this stock.
What sector is Boundless Bio, Inc. in?
Boundless Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BOLD's market cap?
Boundless Bio, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does BOLD pay dividends?
No, Boundless Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
Explore stocks similar to BOLD for comparison